Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Neuland Laboratories reported strong full-year results for FY26 with consolidated revenue from operations of Rs 2,02,299 lakhs, up 37% from Rs 1,47,684 lakhs in FY25. Profit after tax grew 40% to Rs 36,400 lakhs from Rs 26,011 lakhs, while EPS improved to Rs 283.71 from Rs 202.74. The auditors issued an unmodified opinion confirming clean financials. The Board recommended a final dividend of Rs 34 per share (340%) and approved a Rs 143.4 crore capacity expansion at Unit 1 to add 120.5 KL over 12-18 months. An exceptional gain of Rs 7,640 lakhs from investment property sale was recorded. The company also appointed Dr. Mauricio Futran as Additional Director.
The 37% revenue growth and 40% PAT growth reflect strong operational performance across geographies, particularly in Europe and USA. The clean audit opinion and capacity expansion signal confidence in sustained growth, which is positive for shareholders.